Download presentation
Presentation is loading. Please wait.
Published byNatividad Juárez Olivares Modified over 6 years ago
1
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer José Rodrigues-Pereira, MD, Joo-Hang Kim, MD, PhD, Manuel Magallanes, MD, Dae Ho Lee, MD, PhD, Jie Wang, MD, PhD, Vinod Ganju, MD, Luis Martínez-Barrera, MD, Helen Barraclough, MSc, Maximiliano van Kooten, MD, Mauro Orlando, MD Journal of Thoracic Oncology Volume 6, Issue 11, Pages (November 2011) DOI: /JTO.0b013e318226b5fa Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1. Patient flow diagram. Carb, carboplatin; Doc, docetaxel; ITT, intention-to-treat (all randomized patients who received at least one dose of study drug assigned at randomization); Pem, pemetrexed; Q-ITT, qualified-ITT (all randomized patients with nonsquamous histology who received at least one dose of the study drug assigned at randomization). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318226b5fa) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2. Kaplan-Meier survival curves for survival without treatment-emergent grade 3 or 4 toxicity (A), overall survival (B), and progression-free survival (C) in the Pem/Carb and Doc/Carb treatment groups. Carb, carboplatin; CI, confidence interval; Doc, docetaxel; HR, hazard ratio; Pem, pemetrexed; SWT, survival without treatment-emergent toxicity. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e318226b5fa) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.